Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction

Despite the high prevalence of ischemic heart diseases worldwide, no antibody-based treatment currently exists. Starting from the evidence that a specific isoform of the Bone Morphogenetic Protein 1 (BMP1.3) is particularly elevated in both patients and animal models of myocardial infarction, here w...

Descripción completa

Detalles Bibliográficos
Autores principales: Vukicevic, Slobodan, Colliva, Andrea, Kufner, Vera, Martinelli, Valentina, Moimas, Silvia, Vodret, Simone, Rumenovic, Viktorija, Milosevic, Milan, Brkljacic, Boris, Delic-Brkljacic, Diana, Correa, Ricardo, Giacca, Mauro, Maglione, Manuel, Bordukalo-Niksic, Tatjana, Dumic-Cule, Ivo, Zacchigna, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748453/
https://www.ncbi.nlm.nih.gov/pubmed/35013172
http://dx.doi.org/10.1038/s41467-021-27622-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748453/
https://www.ncbi.nlm.nih.gov/pubmed/35013172
http://dx.doi.org/10.1038/s41467-021-27622-9

Ejemplares similares